Quick Links
Contact us
Submit a medical question on an Otsuka product.
To discuss a medical inquiry on an Otsuka product, please call 1-800-441-67631-800-441-6763.
To report an adverse event or a product quality complaint, please call 1-800-438-99271-800-438-9927.
Featured news
Otsuka Pharmaceutical to Acquire Transcend Therapeutics - Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend’s portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Transcend Therapeutics, Inc. (Transcend) announce that the two companies entered into an agreement today, under which Otsuka, through its wholly owned subsidiary Otsuka America, Inc., will fully acquire Transcend. The acquisition is expected to be completed in the second quarter of 2026, subject to the fulfillment of customary closing conditions and required procedures. Read the full press release here.
Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology Highlighting the Impact of APRIL Inhibition
Otsuka Pharmaceutical Development & Commercialization, Inc. today announced new analyses from the Phase 3 VISIONARY trial evaluating VOYXACT® (sibeprenlimab-szsi) in adults with IgA nephropathy (IgAN) at risk for disease progression, demonstrating clinically meaningful improvements across key markers of IgAN.
Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced new open-label extension study data for repinatrabit (JNT-517), demonstrating early and clinically meaningful reductions in blood phenylalanine (Phe) levels (-67% mean change from baseline) in adolescents with phenylketonuria (PKU). These new data, along with the study design for the pivotal global Phase 3 PheORD trial (NCT06971731) in adults, were presented at the 2026 American College of Medical Genetics and Genomics (ACMG) meeting.